Clinical Trial Search

Primary: Safety of Single Infusions of FDP at Increasing Fixed Doses in Normal Healthy Subjects by Evaluating Vital Signs and Laboratory Tests — 4; 4; 4; 4 Participants

Primary: Overall Response Based on RECIST V1.1 Following Oral Doses of Pexidartinib (Efficacy Analysis Set) — 0; 0; 1; 0 Number of participants

Primary: Number of Participants With Treatment-Emergent Treatment Related Adverse Events Following Oral Administration of Quizartinib in Participants With Relapsed or Refractory…

Primary: Maximum Observed Plasma Concentration (Cmax) of Anagrelide (SPD422) — 5.028; 3.180 nanogram per milliliter (ng/mL)

Primary: Maximum Observed Concentration in Plasma (Cmax) of Pexidartinib — 4580; 7090; 3870 ng/mL

Primary: Avobenzone Maximum Concentration — 1.8; 4.3; 4.0; 3.4 ng/mL

Primary: Number of Participants With Local and Systemic Adverse Events During Seven-Day Follow-Up Period — 11; 14; 13; 5 Participants

Primary: Percentage Change in Area Under The Curve (AUC) for Blood Glucose 0-2 Hours — 301.09; 258.66; 248.63; 274.13 mmol x min/L — p=0.1146

Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 Participants

Primary: Number of Participants With Sufficient Collection of Hemopoietic Stem Cells (HSCs) Without Serious Adverse Events — 14 Participants

Primary: Patient Tolerance of Conivaptan — 0; 0; 1; 0 Participants

Primary: Maximum Measured Concentration (Cmax) — 8826; 8856 pg/mL

Primary: Maximum Tolerated Dose (MTD) of LY3076226 — 5.0 milligrams

Primary: Safety and Tolerability of Emodepside After Multiple Doses as Measured by Number of Participants With Adverse Events — 5; 6; 6; 4 Participants

Primary: Number of Subjects With Any and Grade 3 Solicited Local Adverse Events (AE) During a 7-day Follow-up Period — 59; 64; 67; 20 Participants